相关实验视频

Updated: Jan 14, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

巴瓦哈尔科尼向转移素受体,并使葛西他敏化,以影响膀癌的进展

Zihao Zhang^1,2, Chenyue Yuan³, Qintao Ge^1,2

¹Department of Urology Fudan University Shanghai Cancer Center; Center; Department of Oncology, Shanghai Medical College, Fudan University Shanghai China.

|October 20, 2025

概括

巴瓦哈尔科尼 (Bava) 通过向转移素受体 (TFRC) 和表皮生长因子受体 (EGFR) 来克服膀癌中的凝素耐药性. 这种新的方法提高了化疗的疗效,并提供了一个有前途的新疗法策略.

科学领域:

在瘤学瘤学.
药理学药理学是指药理学的学科.
分子生物学分子生物学

背景情况:

凝抗药是膀癌治疗的一个主要挑战,导致疾病复发和进展.
确定克服化疗抵抗的新型治疗策略对于改善患者的治疗结果至关重要.

研究的目的:

识别新型化合物,使膀癌细胞对凝素敏感.
阐明已识别的化合物的作用机制.
评估在临床前模型中将新型化合物与gemcitabine结合的治疗潜力.

主要方法:

膀癌细胞系的高通量药物查.
涉及转移素受体 (TFRC) 和表皮生长因子受体 (EGFR) 抑制的机制研究.
评估细胞铁利用,线粒体呼吸和DNA损伤修复.
在患者衍生异种移植模型中进行组合疗法研究.

主要成果:

巴瓦哈尔科尼 (Bava) 被确定为一种强有力的凝胺敏化剂.
巴瓦抑制TFRC和EGFR,减少铁的流入,并破坏线粒体功能.
Bava-gemcitabine组合通过抑制DNA修复和ATR-CHEK1-E2F1通路来协同增强抗瘤疗效,同时降低RRM1.
提升的TFRC和RRM1表达与膀癌患者的预后不佳相关.

结论:

巴瓦哈尔科尼是第一个通过铁调节克服凝胺耐药性的小分子TFRC抑制剂.
巴瓦 - 杰米西塔宾组合代表了膀癌的有前途的治疗策略.
TFRC和RRM1作为膀癌预后的潜在生物标志物.

关键词:

巴瓦哈尔形形形修复DNA损伤的修复在TFRC和RRM1中.膀癌:膀癌是一种癌症.耐药性耐药性耐药性耐药性耐药性耐药性

更多相关视频

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

Patient-derived Heterogeneous Xenograft Model of Pancreatic Cancer Using Zebrafish Larvae as Hosts for Comparative Drug Assessment

Patient-derived Heterogeneous Xenograft Model of Pancreatic Cancer Using Zebrafish Larvae as Hosts for Comparative Drug Assessment

Published on: April 30, 2019

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: 5-HT₃ Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...